Noble Capital Markets, Inc. Announces Type-1 Diabetes Day- The Beginning of the End; Close to a Cure?

A Panel of World Experts Breaks it all Down in a Virtual Presentation

Boca Raton, Fla., Nov. 23, 2020 (VIA NEWSWIRE) -- Noble Capital Markets, Inc. (“Noble”) announced today that it will host Type-1 Diabetes Day where Dr. Camillo Ricordi and a world-class panel of T1D experts will discuss progress toward a functional cure.

The virtual event “Type-1 Diabetes – The Beginning of the End; Close to a Cure?” is investor focused but will have broad appeal among all interested in the progress toward a functional cure for T1D. It is to be held November 24, 2020, at 12:30 online to all who register here.

Dr. Camillo Ricordi revolutionized a method of transplantation of islet cells (cells that produce insulin) 32 years ago. His method remains the gold standard today. The promise of overcoming one of the most challenging problems with any transplantation occurred when an anti-rejection antibody being explored for ALS was coupled with the transplantation. New islet cells had previously been rejected by the host. The anti-rejection antibody was key to this procedure jumping several steps closer to success.

The Panel will be moderated by Noble’s Nathan Cali, Managing Director, Head of Healthcare Investment and Merchant Banking, with a primary focus on the Novus Therapeutics, Inc. (NASDAQ:NVUS) - CD40/CD40L - FDA Phase II toxicity and efficacy trials and ongoing progress toward a functional cure with islet cell transplantation. The world-renowned panelists include:

  • Dr. Camillo Ricordi, Director of the Diabetes Research Institute at the University of Miami School of Medicine – Ranked as the World Leader in Islet Cell Transplant.
  • Dr. James Markmann, Chief of the Division of Transplant Surgery and Director of Clinical Operations at the Transplant Center at Massachusetts General Hospital, and the Claude Welch Professor of Surgery at Harvard Medical School.
  • Dr. Norma Sue Kenyon, Martin Kleiman Professor of Surgery, Microbiology and Immunology and Biomedical Engineering at the Diabetes research Institute.
  • Dr. David Gros, Chief Executive Officer Novus Therapeutics; Dr. Steven Perrin, President & CSO, Novus Therapeutics.
  • Eric Paslay, two-time Grammy award nominee country recording artist, & owner of The Country Note, a podcast featuring patients who battle diabetes.

November is Diabetes Awareness Month; this expert panel presentation will elevate awareness for investors and others interested in promising progress toward a functional cure for T1D. The presentation is expected to last two hours and will be held at 12:30 PM (register to attend) on November 24, 2020. Attendance is open and at no cost to all who register for T1D-Day. As conference time is limited, Noble requests that only investment focused attendees participate by asking questions of the panelists.

Who should attend Type-1 Diabetes Day?
Investors, including institutions, family offices, investment advisors, hedge funds, equity analysts, private equity & venture capital firms, independent brokers, wealth managers, and self-directed investors, will benefit from attending.
The subject is of interest to those within the investment community, medical practitioners and others interested in the future of T1D. “Noble is proud of its part in the progression toward a cure,” said Nico Pronk, CEO/President of Noble, he added, “Although we had hoped to have an in-person conference featuring this panel, we’re taking advantage of the online platform and making sure many more who are interested in this subject can attend without the need to travel farther than their desktop.”

About Noble Capital Markets, Inc.
Noble Capital Markets is a research-driven boutique investment bank that has supported small & micro-cap companies since 1984. As a FINRA and SEC licensed, broker-dealer Noble provides institutional-quality equity research, merchant and investment banking, wealth management, and order execution services. Noble launched - an investment community dedicated exclusively to small and micro-cap companies and their industries in 2018. Channelchek is tailored to meet the needs of self-directed investors and financial professionals. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 public emerging growth companies are listed on the site, with growing content including research, webcasts, podcasts, and balanced news.

Click here to register


General Information: